Based on the continuous pricing pressure going forward, we reiterate the revenue forecast to range from 0% to 5% growth year over year from fiscal year 2013, along with a 10% net margin. The forecasted net income guidance excluded any non-cash expenses associated with stock compensation plans or stock option expenses.
We believe the following factors will influence the future growth perspectives of our Company:
Market expansion and revenue growth of TPI's core product portfolio led by flagship product GMOL;2)
Gradual ramp up of JCM revenue in the fiscal year 2014;3)
The stabilization of generic sales following the progressive pricing restrictions amid the ongoing healthcare reform;4)
Meaningful TMT distribution revenue contribution; and5)
QLF relocation and smooth transition of production capacity.Management will continue to evaluate the Company's business outlook and communicate any changes on a quarterly basis or as when appropriate.
Conference CallSenior management of TPI will host its earnings conference call for the first quarter of fiscal year 2014 ended September 30, 2013 to be held at 8:30 a.m. ET on Friday, November 15th, 2013.
Interested parties may access the call by dialing
1-480-629-9664 It is advisable to dial in approximately 5 minutes prior to the start of the call.
Replay Dial-In Numbers:
11/15/13 @ 11:30 am Eastern TimeTo:
11/29/13 @ 11:59 pm Eastern TimeReplay Pin Number:
|SOURCE Tianyin Pharmaceutical Inc.|
Copyright©2012 PR Newswire.
All rights reserved